Seres Therapeutics’ (MCRB) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a research note issued to investors on Thursday,Benzinga reports. Chardan Capital currently has a $1.25 target price on the biotechnology company’s stock.

Several other equities analysts also recently weighed in on the company. The Goldman Sachs Group dropped their price target on Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating for the company in a research report on Friday, March 14th. StockNews.com raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat, Seres Therapeutics currently has an average rating of “Hold” and a consensus target price of $4.00.

Seres Therapeutics Price Performance

MCRB stock opened at $0.71 on Thursday. Seres Therapeutics has a 12 month low of $0.54 and a 12 month high of $1.53. The firm has a market capitalization of $123.84 million, a PE ratio of -3.09 and a beta of 2.19. The company’s 50 day simple moving average is $0.78 and its 200-day simple moving average is $0.83.

Hedge Funds Weigh In On Seres Therapeutics

Several institutional investors have recently added to or reduced their stakes in MCRB. Avantax Advisory Services Inc. grew its holdings in Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 28,500 shares during the period. Jane Street Group LLC grew its holdings in Seres Therapeutics by 181.4% in the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 37,866 shares during the period. Virtu Financial LLC increased its position in Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC increased its position in Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 22,250 shares during the last quarter. Finally, Northern Trust Corp raised its stake in Seres Therapeutics by 20.4% during the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock worth $218,000 after purchasing an additional 44,461 shares during the period. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.